valproic acid (CT-010) / Cerebral Therap - LARVOL DELTA

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion (clinicaltrials.gov) - P1/2 | N=20 | Terminated | Sponsor: Cerebral Therapeutics LLC | Trial completion date: Dec 2026 ➔ Mar 2024 | Enrolling by invitation ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Mar 2024; Company Decision

Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Epilepsy

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization (clinicaltrials.gov) - P2 | N=30 | Terminated | Sponsor: Cerebral Therapeutics LLC | N=70 ➔ 30 | Trial completion date: Jul 2024 ➔ Mar 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2024 ➔ Mar 2024; Company Decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Epilepsy

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion (clinicaltrials.gov) - P1/2 | N=5 | Enrolling by invitation | Sponsor: Cerebral Therapeutics LLC | Trial completion date: Oct 2024 ➔ Dec 2026 | Trial primary completion date: Jan 2023 ➔ Dec 2026

Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Cerebral Therapeutics LLC | Trial completion date: Sep 2022 ➔ Jul 2024 | Trial primary completion date: Jul 2022 ➔ Jul 2024

Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy • Immunology

Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing (Businesswire) - "Cerebral Therapeutics...announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management, Perceptive Advisors, Vivo Capital LLC, and Granite Point Capital Management L.P....The Company plans to use Series C proceeds to complete an international Phase 2 double-blind, randomized, placebo-controlled clinical trial of its proprietary investigational drug (CT-010) for the treatment of uncontrolled seizures in patients with medically refractory epilepsy..."

Financing • CNS Disorders • Epilepsy

Long-Term Experience with Intracerebroventricular Sodium Valproate Administration (AES 2021) - "ICV administration of sodium valproate is safe and effective long-term using an implanted drug delivery system. Clinically significant reduction of seizures was observed in all patients, and the benefits have been maintained over periods of years. No dose limiting side effects of sodium valproate developed, despite the high concentrations reached."

CNS Disorders • Epilepsy • Immunology

Determination of Valproic Acid Distribution and Absolute Quantification in Brain by MALDI MSI Following Continuous Intracerebroventricular Infusion (AES 2021) - "For the detection of VPA and its metabolites, mass spectra were acquired in positive mode with a Continuous Accumulation of Selected Ions (CASI) mode of acquisition within m/z 338 to 358 Da range and a spatial resolution of 100 µm. MSI helped better understand the distribution of VPA, its metabolites, and the impact of these on GABA concentrations in different regions of the brain. One effect of ICV infusion of sodium valproate in male rat brains is an increase in GABA."

CNS Disorders • Epilepsy

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization (clinicaltrials.gov) - P2; N=70; Recruiting; Sponsor: Cerebral Therapeutics LLC; Trial completion date: Jul 2024 ➔ Sep 2022

Clinical • Trial completion date • CNS Disorders • Epilepsy • Immunology

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion (clinicaltrials.gov) - P1/2; N=5; Enrolling by invitation; Sponsor: Cerebral Therapeutics LLC; Trial completion date: Jan 2023 ➔ Oct 2024

Clinical • Trial completion date • CNS Disorders • Epilepsy • Immunology

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures (clinicaltrials.gov) - P1/2; N=6; Completed; Sponsor: Cerebral Therapeutics LLC; Active, not recruiting ➔ Completed; Trial primary completion date: Nov 2020 ➔ Jun 2021

Clinical • Trial completion • Trial primary completion date • CNS Disorders • Epilepsy • Immunology • MRI